Immunomodulating effects of 13-cis retinoic acid on the IgG and IgM response of BALB/c mice.
The results reported here provide information on the effects of 13-cis retinoic acid (13-cRA) on the IgG and IgM responses in BALB/c mice. For these studies, a suboptimum immunizing concentration of ovalbumin (1 microgram) was used. BALB/c mice were given either 13-cRA or control beadlets (gel) as either 1 dose (at day -1) or 4 doses (at week -3, -2, -1, and day -1) prior to primary immunization, or 4 doses prior to, and 4 doses after, primary immunization (week -3, -2, -1, day -1, week 1, 2, 3, and day 27). The results consistently showed no primary antibody response and excellent secondary antibody levels in all 13-cRA-treated groups. Attempts to determine whether the 13-cRA affected the afferent or efferent phase of antibody induction by varying the time of the administration of a single 13-cRA dose, relative to immunization, showed no difference in the results in animals treated on day -2 to day 3.
D000276:Adjuvants, Immunologic; D000818:Animals; D000917:Antibody Formation / Q000187:drug effects*; D004334:Drug Administration Schedule; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D007074:Immunoglobulin G / Q000096:biosynthesis*; D007075:Immunoglobulin M / Q000096:biosynthesis*; D015474:Isotretinoin; D051379:Mice; D008807:Mice, Inbred BALB C; D010047:Ovalbumin / Q000276:immunology; D014212:Tretinoin / Q000008:administration & dosage / Q000494:pharmacology*
D000276:Adjuvants, Immunologic; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D014212:Tretinoin; D010047:Ovalbumin; D015474:Isotretinoin